nach oben

Erschienen in:

19.08.2021 | Multiple Sklerose | Zertifizierte Fortbildung Neurologie Zur Zeit gratis

COVID-19

Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie

verfasst von: Dr. med. Marc Pawlitzki, Univ.-Prof. Dr. med. Dr. rer. nat. Sven G. Meuth

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 7-8/2021

Einloggen, um Zugang zu erhalten

Auszug

Vor dem Hintergrund der anhaltenden COVID-19(Corona-Virus-Disease-19)-Pandemie besteht weiterhin eine Unsicherheit aufseiten von Patienten und Behandlern im Umgang mit Immuntherapien zur Behandlung der Multiplen Sklerose (MS). Dieser Artikel soll die aktuellen Zusammenhänge zwischen der MS-Erkrankung und dem Risiko einer COVID-19-Erkrankung beleuchten sowie praktische Handlungsempfehlungen im Umgang mit Immuntherapien liefern. …

Portaccio E, Fonderico M, Hemmer B, et al. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler 2021:13524585211005339

Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study. Mult Scler Relat Disord 2020; 46:102512

Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 2021

Ciampi E, Uribe-San-Martin R, Carcamo C. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Mult Scler Relat Disord 2020;42:102204

Fan M, Qiu W, Bu B, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020;

Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol 2020;77:1079-1088

Mohn N, Konen FF, Pul R, et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020;9.

Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 2020;56:102822

Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017;376:209-220

10.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS. Interferon beta-1a and beta-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol 2018;14:137-153

11.

Reder AT, Centonze D, Naylor ML, et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs 2021;35:317-330

12.

Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021;384:497-511

13.

Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin 2015;1

14.

Morales FS, Koralnik IJ, Gautam S, Samaan S, Sloane JA. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neurol 2020;267:125-131

15.

Mantero V, Abate L, Basilico P, et al. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J Neurol 2020

16.

Capone F, Motolese F, Luce T, Rossi M, Magliozzi A, Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord 2021;48:102734

17.

Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Mult Scler Relat Disord 2021;51:102929

18.

Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord 2019;12:1756286419836913

19.

Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 2021:13524585211012227

20.

Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs 2021;35:385-402

21.

Tasat DR, Yakisich JS. Rationale for the use of sphingosine analogues in COVID-19 patients. Clin Med (Lond) 2021;21:e84-e87

22.

Pantazou V, Pot C, Du Pasquier R, Le Goff G, Theaudin M. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Mult Scler Relat Disord 2021;51:102918

23.

Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015;16:16414-16439

24.

Hartung HP, Mares J, Barnett MH. Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Mult Scler 2020;26:737-740

25.

Mohn N, Pfeuffer S, Ruck T, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm 2020;7

26.

Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 2020;16:56-62

27.

Ellrichmann G, Bolz J, Peschke M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 2019;266:57-67

28.

Trojano M, Ramio-Torrenta L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021:13524585211003020

29.

Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025

30.

Otero-Romero S, Ascherio A, Lebrun-Frenay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-328

31.

Nguyen J, Hardigan P, Kesselman MM, Demory Beckler M. Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. Mult Scler Relat Disord 2021;48:102698

32.

Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021;27:864-870

33.

Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 2021;356:577599

34.

Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020;45:102439

35.

von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2018;5:e409

36.

Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm 2015;2:e70

37.

Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 2015;84:872-879

38.

Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011;69:408-413

39.

Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol 2018;25:527-534

40.

Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders 2021;14:17562864211012835

41.

Centonze D, Rocca MA, Gasperini C, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 2021

42.

Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946-1953

43.

Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol 2013;20:975-980

44.

Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-161

45.

Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 2020;95:e1999-e2008

46.

Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2014;341:22-27

47.

Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res 2012;34:730-733

48.

Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler 2014;20:1074-1080

Titel: COVID-19
Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie
verfasst von: Dr. med. Marc Pawlitzki
Univ.-Prof. Dr. med. Dr. rer. nat. Sven G. Meuth
Publikationsdatum: 19.08.2021
Verlag: Springer Medizin
Schlagwörter: Multiple Sklerose
Ocrelizumab
COVID-19
SARS-CoV-2
Impfungen
Lymphopenie
Natalizumab
Mitoxantron
Teriflunomid
Dimethylfumarat
Alemtuzumab
Cladribin
Ocrelizumab
Siponimod
Alemtuzumab
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 7-8/2021
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-021-2009-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7-8/2021

Mehr Schaden als Nutzen

Gestörte Hirnaktivität medikamentös stützen

Migräne: Valproat intravenös als Akutbehandlung?

Psychiatrisch-psychotherapeutische Spitzenforschung in Deutschland

Nutzen von präklinischen Schlaganfallskalen

Antidepressiva bei postnataler Depression